Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
72 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Skin And Soft Tissue Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Skin And Soft Tissue Infections - Pipeline Review, H2 2014', provides an overview of the Skin And Soft Tissue Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Skin and Soft Tissue Infections Overview 7 Therapeutics Development 8 Pipeline Products for Skin And Soft Tissue Infections - Overview 8 Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis 9 Skin And Soft Tissue Infections - Therapeutics under Development by Companies 10 Skin And Soft Tissue Infections - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Skin And Soft Tissue Infections - Products under Development by Companies 14 Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development 15 Atox Bio Inc. 15 Cubist Pharmaceuticals, Inc. 16 Dong-A Socio Group 17 Durata Therapeutics, Inc. 18 Melinta Therapeutics, Inc 19 Takeda Pharmaceutical Company Limited 20 Wockhardt Limited 21 Skin And Soft Tissue Infections - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 AB-103 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ceftaroline fosamil - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 dalbavancin - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 KBP-7072 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RX-04 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for SSTI and CAP Infections - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tedizolid phosphate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 tedizolid phosphate - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 VAL-301 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 WCK-2349 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Skin And Soft Tissue Infections - Recent Pipeline Updates 46 Skin And Soft Tissue Infections - Dormant Projects 63 Skin And Soft Tissue Infections - Product Development Milestones 64 Featured News & Press Releases 64 Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority 64 Sep 03, 2014: Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 64 Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections 65 Aug 05, 2014: Cubist's Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations 65 Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections 66 Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review 67 Dec 23, 2013: European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin 68 Dec 03, 2013: Durata Therapeutics Submits Marketing Authorization Application for Dalbavancin 68 Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial 69 Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 72 Disclaimer 72
List of Tables Number of Products under Development for Skin And Soft Tissue Infections, H2 2014 8 Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Skin And Soft Tissue Infections - Pipeline by Atox Bio Inc., H2 2014 15 Skin And Soft Tissue Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 16 Skin And Soft Tissue Infections - Pipeline by Dong-A Socio Group, H2 2014 17 Skin And Soft Tissue Infections - Pipeline by Durata Therapeutics, Inc., H2 2014 18 Skin And Soft Tissue Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 19 Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20 Skin And Soft Tissue Infections - Pipeline by Wockhardt Limited, H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Skin And Soft Tissue Infections Therapeutics - Recent Pipeline Updates, H2 2014 46 Skin And Soft Tissue Infections - Dormant Projects, H2 2014 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.